Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial
May 31, 2026
,
Atkins, M. et al.
ASCO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)
First-line Botensilimab and Balstilimab OPtimization in Microsatellite Stable Colorectal Cancer without liver, bone, or brain metastasis
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 26, 2025
,
DeVito et al.
Balstilimab (PD-1 inhibitor)
Biomarker analysis from phase 2 study of agenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 24, 2025
,
Cytryn et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Biomarker Analysis From a Phase II Study of AgenT-797 (invariant natural killer T cells) with Botensilimab (Fc-enhanced CTLA-4 inhibitor) and Balstilimab (anti-PD-1) in PD-1 Refractory Gastroesophageal Cancer
AACR
American Association for Cancer Research, Immuno-Oncology (AACR-IO)
February 24, 2025
,
Cytryn et al.
Balstilimab (PD-1 inhibitor)
Botensilimab (Fc-enhanced anti-CTLA-4)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Other Articles & Publications
Journal of Clinical Oncology
February 14, 2025
,
Wilky et al.